• Opko Health Inc., of Miami, surpassed 50 percent enrollment in the second Phase III trial of Rayaldy, an oral vitamin D pro-hormone treatment for patients with secondary hyperparathyroidism, Stage III or IV chronic kidney disease and vitamin D insufficiency. Identical to the initial Phase III, the randomized, double-blind, placebo-controlled, multisite study is designed to establish the safety and efficacy of Rayaldy.